A Study to Evaluate the Safety and Efficacy of Celgosivir in Patients With Chronic Hepatitis C Genotype 1 Infection

B

BioWest Therapeutics

Status and phase

Completed
Phase 2

Conditions

Hepatitis C, Chronic

Treatments

Drug: Celgosivir

Study type

Interventional

Funder types

Industry

Identifiers

NCT00157534
HCV-04-001

Details and patient eligibility

About

The objective of the study is to evaluate the safety and efficacy of celgosivir for 12 weeks in patients with chronic hepatitis C genotype 1 infection.

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

* The patient must be 18 to 65 years of age, inclusive. * Primary diagnosis of chronic HCV infection.

Exclusion criteria

* Patients who did not respond or relapsed following therapy with interferon.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems